Related references
Note: Only part of the references are listed.BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial
R. Ljung et al.
HAEMOPHILIA (2016)
Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators
J. Dodt et al.
HAEMOPHILIA (2015)
Current laboratory practices in the diagnosis and management of haemophilia: a global assessment
S. Kitchen et al.
HAEMOPHILIA (2015)
Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
K. Kavakli et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Potency Labeling of Novel Factor VIII and Factor IX Concentrates: Past Experience and Current Strategy
Anthony R. Hubbard
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2015)
Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories
J. M. Sommer et al.
HAEMOPHILIA (2014)
Monitoring of modified factor VIII and IX products
S. Kitchen et al.
HAEMOPHILIA (2014)
Assaying FVIII activity: one method is not enough, and never was
M. Makris et al.
HAEMOPHILIA (2014)
Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A
J-M. Gu et al.
HAEMOPHILIA (2014)
Guidelines for the management of hemophilia
A. Srivastava et al.
HAEMOPHILIA (2013)
Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory
M. Cauchie et al.
HAEMOPHILIA (2013)
International comparative field study of N8 evaluating factor VIII assay performance
D. Viuff et al.
HAEMOPHILIA (2011)
Emerging technologies and quality assurance: The United Kingdom National External Quality Assessment Scheme perspective
Ian Jennings et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2007)
Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays
J Ingerslev et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards
M Morfini et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Coagulation and chromogenic assays of factor VIII activity: General aspects, standardization, and recommendations
TW Barrowcliffe et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2002)
Potency estimation of recombinant factor VIII: effect of assay method and standard
AR Hubbard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
